Tag: MindMed - Psilocybin Alpha

New Resource: Psychedelic Legalization & Decriminalization Tracker

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Post published:September 23, 2021
Post category:Press Release

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

Post published:September 2, 2021
Post category:Press Release

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

Post published:August 24, 2021
Post category:Press Release

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Post published:August 17, 2021
Post category:Press Release

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

Post published:August 12, 2021
Post category:Press Release

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

Post published:August 10, 2021
Post category:Press Release

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

Post published:August 3, 2021
Post category:Press Release

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

Post published:July 28, 2021
Post category:Press Release

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

Post published:July 8, 2021
Post category:Press Release

MindMed Included in FTSE Russell 3000® Index

MindMed Included in FTSE Russell 3000® Index

Post published:June 28, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.